ReNeuron Group Plc
Developing the next generation of Engineered Exosomes.
Developing the next generation of Engineered Exosomes.
ReNeuron Group Plc is a biotechnology startup based in United Kingdom that is dedicated to developing the next generation of Engineered Exosomes. The company's flagship technology, CustomEx exosome platform, is designed to produce exosomes with unique tissue targeting tropisms, allowing for the delivery of a payload of choice to a preferred cell type. ReNeuron's ultimate mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs in the fields of Biotechnology and Health Care. Founded in 1997, ReNeuron Group Plc has garnered significant attention from investors. Its last investment of £68.40MPost-IPO Equity was secured on 10 July 2015 from a notable investor, Woodford Patient Capital Trust. This infusion of capital underscores the growing interest in ReNeuron's innovative approach to addressing unmet medical needs through exosome therapeutics. With a clear focus on leveraging its proprietary technology to advance the field of regenerative medicine, ReNeuron holds promise as a key player in the biotech landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | £68.40M | 1 |
|
10 Jul 2015 |
| Post-IPO Equity | £25.35M | 1 |
|
22 Jul 2013 |
| Post-IPO Equity | €4.70M | - | 22 Feb 2010 | |
| Post-IPO Equity | €5.00M | 1 | Matrix Corporate Capital | 26 Nov 2009 |
| Venture Round | $7.50M | 1 |
|
01 Jan 1997 |
No recent news or press coverage available for ReNeuron Group Plc.
We care about your data, and we'd love to use cookies make your experience better.
